Q2 2026 saw 10% organic sales growth and 23% EPS growth, led by Artegraft and strong European performance. Guidance was reduced due to FX, Middle East export delays, and cardiac allograft supply constraints, but margin expansion and infrastructure investments support long-term growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.